Here are a few analogies for Sunshine Biopharma:

• Think of it as an early-stage Gilead Sciences, dedicated to discovering new cancer and antiviral drugs, that also sells health supplements.
• It's like a smaller version of Pfizer or Merck focused on developing novel cancer and coronavirus treatments, with an additional business selling nutritional supplements.

• Adva-27a: An anticancer drug candidate designed to treat various cancers and kill multidrug-resistant cancer cells.
• SBFM-PL4: An anti-coronavirus treatment compound currently under development.
• Essential 9: A nutritional supplement tablet.
• Essential Calcium-Vitamin D: A nutritional supplement providing calcium and vitamin D.
• Other Science-Based Nutritional Supplements: A category of additional nutritional supplements developed and marketed by the company.

Based on the provided description, Sunshine Biopharma, Inc. (SBFM) appears to sell its nutritional supplements primarily to individuals. While the company is heavily involved in the research and development of anticancer drugs and anti-coronavirus treatments, these products are still in development and not actively being sold to major customers described in the text.

For its nutritional supplements (Essential 9 and Essential Calcium-Vitamin D), Sunshine Biopharma primarily serves the following categories of individual customers:

1. General Health-Conscious Consumers: Individuals who proactively seek to maintain or enhance their overall health and well-being through daily nutritional intake, including essential vitamins, minerals, and amino acids.
2. Individuals with Specific Nutritional Needs: Consumers looking to address particular dietary deficiencies or support specific health areas, such as bone health (with Essential Calcium-Vitamin D) or ensuring comprehensive essential nutrient intake (with Essential 9).
3. Consumers Seeking Science-Based Supplements: Individuals who prioritize nutritional supplements developed with a scientific foundation, aligning with Sunshine Biopharma's background as a pharmaceutical and R&D-focused company.

Dr. Steve N. Slilaty

Chairman, President and Chief Executive Officer

Dr. Steve N. Slilaty is an accomplished scientist and business executive, serving as the Chairman, President, and Chief Executive Officer of Sunshine Biopharma, Inc. since October 15, 2009. He holds a Bachelor of Science degree in Genetics and Biochemistry from Cornell University and a Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. Dr. Slilaty has founded three biotechnology companies, one of which, Genomics One Corporation (now Alert B&C Corporation), he took public, achieving a $1 billion market capitalization. His other ventures include Quantum Biotechnologies Inc. (later Qbiogene Inc.), which grew to over $60 million in annual sales and is now part of MP Biomedicals, and Advanomics Corporation, a privately held company where he has served as President and Chief Scientific Officer since February 2002. Dr. Slilaty's scientific contributions include the discovery of a new class of enzymes and the development of the TrueBlue Cloning System, a key technology for the Human Genome Project. He also previously served as a research team leader at the Biotechnology Research Institute of the National Research Council of Canada.

Camille Sebaaly

CFO, Secretary & Director

Camille Sebaaly serves as the Chief Financial Officer, Secretary, and a Director of Sunshine Biopharma, Inc. No additional background information on previous companies founded or managed, company sales, or private equity involvement is available in the provided sources.

Michel Roy

Chief Commercial Officer

Michel Roy was appointed Chief Commercial Officer of Sunshine Biopharma, Inc. effective January 15, 2025, bringing over 20 years of experience in the pharmaceutical industry. He is responsible for overseeing the company's commercial strategy, including sales, marketing, and business development. Prior to joining Sunshine Biopharma, Mr. Roy founded and led the Canadian operations for Shilpa Medicare from 2020 to 2024. From 2014 to 2020, he was the Vice President of Business Development and Sales at Intas Pharmaceuticals. Mr. Roy holds an Executive MBA from John Molson School of Business, an M.Sc. from Université de Montréal, and a Bachelor of Commerce in economics from Concordia University.

Malek Chamoun

Chief Development Officer

Malek Chamoun is the Chief Development Officer at Sunshine Biopharma, Inc. No additional background information is available in the provided sources.

Robert Ferreira

President of Sunshine Bio Investments Inc.

Robert Ferreira serves as the President of Sunshine Bio Investments Inc., a subsidiary of Sunshine Biopharma, Inc. No additional background information is available in the provided sources.

For Sunshine Biopharma (SBFM), key risks to the business primarily revolve around its financial stability, the inherent challenges of drug development, and its reliance on a pipeline that has yet to yield significant commercial success.

1. Funding Uncertainty and Dilution Risk
   Sunshine Biopharma faces significant funding uncertainty for its future research and development (R&D) initiatives. A Q3 2025 filing indicated "no committed sources of capital" for future R&D, which creates critical risks for investors. While existing cash and generated sales are projected to cover operations for the next 24 months, this specifically excludes capital for major future R&D activities, clinical trials, and expansion of generic pharmaceutical operations, thus leaving the company's long-term growth trajectory unsecured. To secure necessary capital for these growth initiatives, Sunshine Biopharma will likely need to raise funds through equity offerings, which would further dilute existing shareholders. The company has a history of substantial increases in common shares outstanding and has posted six consecutive years of quarterly losses as of Q3 2025. For example, in the first nine months of 2021, the company incurred $10.7 million in losses from costly convertible debt financing for R&D. This ongoing need for external financing in a development-stage company is a known risk that can lead to operational delays or even the cessation of crucial R&D programs.

2. Clinical Trial and Regulatory Approval Risk
   As a pharmaceutical company focused on drug development, Sunshine Biopharma is inherently exposed to the high risks associated with clinical trials and regulatory approvals. The company's ability to generate substantial product revenues largely depends on the successful development and commercialization of its proprietary drug candidates, such as Adva-27a (an anticancer drug) and SBFM-PL4 (an anti-coronavirus treatment). However, Sunshine Biopharma has not yet received regulatory approval for any of its proprietary drug development candidates from the FDA. There is no assurance that the FDA or other regulatory bodies will approve its drug candidates in a timely manner, or at all. The drug development process is lengthy, costly, and complex, with a high rate of failure; many products subjected to clinical testing do not demonstrate statistical significance above a placebo. Any failure to obtain regulatory approval would severely harm the company's business by preventing the commercialization of its products.
3. Dependence on an Unproven Pipeline with a High Burn Rate
   While Sunshine Biopharma does generate revenue, primarily from its Canadian generics subsidiary, Nora Pharma, it remains "deep in the red" with a history of unprofitability. The company's revenue from non-prescription over-the-counter supplements represents less than 3% of total sales. The long-term financial health and growth of the company are heavily dependent on the potential of its development pipeline (e.g., K1.1 mRNA program, Adva-27a, SBFM-PL4) to offset its historical and ongoing losses. However, the success of these pipeline assets is not guaranteed, and the development of Adva-27a has been paused. For a small pharmaceutical company with a limited number of drug candidates, the failure or delay of even one key product in development could have a disproportionately negative impact on its financial viability and future prospects.

The diminishing market opportunity and reduced public health urgency for new broad-spectrum anti-coronavirus treatments. This is driven by widespread global vaccination, the availability of existing effective antiviral medications, and the reclassification of COVID-19 as an endemic rather than a pandemic threat, all of which reduce the commercial viability and potential demand for SBFM-PL4, a compound still in development.

Sunshine Biopharma (NASDAQ: SBFM) operates in the pharmaceutical and nutritional supplement industries, focusing on developing anticancer drugs, anti-coronavirus treatments, and marketing nutritional supplements. The addressable markets for its main products and services are substantial both globally and in the U.S.

Anticancer Drugs (Adva-27a)

Sunshine Biopharma's lead anticancer drug candidate, Adva-27a, targets a wide range of cancers, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, pancreatic, breast, small-cell lung, and uterine sarcoma cells.

• The global anticancer drugs market was valued at approximately USD 173.52 billion in 2024 and is projected to reach USD 375.32 billion by 2032.
• In the U.S. alone, the oncology drugs market was valued at USD 85.64 billion in 2024 and is projected to reach USD 189.55 billion by 2033.
• More specifically, the global market for pancreatic cancer treatment, which Adva-27a is being developed to treat, was valued at USD 2.47 billion in 2022 and is expected to grow to USD 7.88 billion by 2030.

Anti-Coronavirus Treatment (SBFM-PL4)

The company is developing SBFM-PL4 as an anti-coronavirus treatment compound.

• The global anti-viral therapeutics market was estimated at USD 56.71 billion in 2025 and is projected to reach USD 64.01 billion by 2031.
• The market for specific antiviral drugs for COVID-19 globally was approximately USD 15.23 billion in 2025, with projections to grow to USD 33.17 billion by 2030.
• The U.S. antiviral drugs market was estimated at USD 26.41 billion in 2024 but is projected to see a decline to USD 23.61 billion by 2030, largely due to decreasing demand for COVID-19-specific antivirals.

Nutritional Supplements (Essential 9, Essential Calcium-Vitamin D, and other science-based nutritional supplements)

Sunshine Biopharma also offers nutritional supplements such as Essential 9 and Essential Calcium-Vitamin D.

• The global nutritional supplements market was estimated at USD 517.09 billion in 2025 and is projected to reach USD 862.51 billion by 2033.
• In the U.S., the dietary supplement market reached USD 69.3 billion in 2024. The U.S. nutrition supplements market size is predicted to increase from USD 115.68 billion in 2026 to nearly USD 182.55 billion by 2035.

Expected Drivers of Future Revenue Growth for Sunshine Biopharma (SBFM) Over the Next 2-3 Years:

1. Expansion of Generic Pharmaceutical Portfolio: Sunshine Biopharma's primary revenue engine is its Canadian generics subsidiary, Nora Pharma. The company continues to launch new generic prescription drugs in Canada, with recent additions including domperidone, pravastatin, doxycycline, and gabapentin. Further new product launches within this segment are expected to drive consistent revenue growth over the next 2-3 years.
2. Growth in the Biosimilars Market: The company's entry into the biosimilars market with products such as NIOPEG (a biosimilar comparable to NEULASTA) in Canada marks a strategic expansion into higher-margin therapeutic areas. Continued commercialization and potential additional biosimilar launches are anticipated to contribute significantly to revenue growth.
3. Advancement of Proprietary Anticancer Drug Adva-27a: Adva-27a, Sunshine Biopharma's lead anticancer compound, is in the IND-Enabling stage of development, with plans to initiate Phase I clinical trials for pancreatic cancer and multidrug-resistant breast cancer. Progress through these clinical milestones within the next 2-3 years could attract strategic partnerships or licensing agreements, potentially generating upfront payments or milestone revenues. A new patent filing, if granted, could extend its exclusivity until January 2033.
4. Development of K1.1 mRNA for Liver Cancer: The K1.1 mRNA program, an mRNA therapeutic for liver cancer, has shown promising results in preclinical studies by demonstrating measurable tumor reduction in liver cancer models. Continued positive preclinical data and progression of this program are expected to enhance the company's valuation and could lead to collaborations or funding that contribute to revenue within the timeframe.

Share Issuance

• In February 2022, Sunshine Biopharma completed a firm commitment underwritten public offering, generating aggregate gross proceeds of $8 million from the sale of 1,882,353 units, each consisting of one share of common stock and two warrants to purchase additional shares.
• The number of shares outstanding for SBFM increased by 1,977.26% in one year.
• The company had follow-on equity offerings of $32.25 million and $2.46 million, as mentioned in updates around August and April.

Inbound Investments

• No information available regarding large inbound investments by third-parties within the last 3-5 years.

Outbound Investments

• Sunshine Biopharma acquired Nora Pharma for C$30 million.
• In October 2025, the Board approved a $5 million strategic investment in Bitcoin (BTC) as a treasury reserve asset.

Capital Expenditures

• Capital expenditures in the last 12 months were approximately -$278,130 (a negative value indicating outflows).
• Cash flow from investing activities was -$1.317 million in the third quarter of 2025, which reflects continued capital expenditure.
• The company's research and development costs significantly increased to $672,000 in 2021, up from $2,000 in 2020, as funding for drug development projects became available.